Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation

NCT ID: NCT00678366

Last Updated: 2011-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study intends to investigate the use of a novel gaz-composition used during laparoscopy upon pain and inflammation in the post-operative period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Laparoscopic surgery was introduced by gynaecologists in a search for a minimally invasive surgical approach. Laparoscopy is now generally accepted and widely used in different medical fields (gynaecology, digestive surgery, oncology, etc.,.).

1. CO2 pneumoperitoneum and pain:

Carbon dioxide is generally used to induce and maintain a pneumoperitoneum. Following a diagnostic procedure post-operative pain is generally low. For more extensive laparoscopic surgery, pain is related to the type of surgery. It has been suggested that pain also increases with the duration of surgery.
2. CO2 pneumoperitoneum and inflammation Different immune mediators were already evaluated during laparoscopic surgery. On peripheral blood interleukin-6, C-reactive protein, tumor necrosis factor, interleukin-1, histamine response, total leukocyte counts and T-lymphocyte populations, delayed-type hypersensitivity and neutrophils activation and function were evaluated. Local peritoneal host defences such as macrophage activation and function and leukocyte function have also been studied.

Laparoscopic surgery is associated with less post-operative inflammatory reaction and less immune activation then laparotomy. (1-2).

The degree of alteration in C-reactive proteins was noted to be a 5 fold increase after laparoscopic cholecystectomy (3).

Peripheral leukocyte populations may not be the principal determinant of an acute-phase response as much as an hepatic response to stress and injury. Kloosterman (4) has demonstrated a transient increase in granulocyte numbers after open cholecystectomy but not after laparoscopic cholecystectomy.

Interleukin-6 levels have been noted to be reduced in patients undergoing laparoscopic procedures compared to traditional laparotomy, with a linear correlation between peak concentrations of IL-6 and C-reactive proteins (3).

West (5) investigated the production of cytokines in peritoneal macrophages incubated in carbon dioxide. Macrophage TNF and IL-1 responses to bacterial endotoxin were lower for macrophages incubated in carbon dioxide than in either air or helium. A proposed mechanism for this difference was that carbon dioxide affected the intracellular medium by creating a more acidic environment. He speculates that the impairment in peritoneal macrophage cytokine production may contribute to an apparent lack of inflammatory systemic response during laparoscopic surgery rather than the physiologic stress of the surgery itself. This provides a potential molecular mechanism to explain peritoneal macrophage immunosuppression.
3. Effects of adding 2-4 % of oxygen to the CO2 pneumoperitoneum Adding 4% of oxygen to the CO2 results in a partial oxygen pressure of 30 mmHg (4% of 760 atmospheric pressure + 15 mmHg insufflation pressure) which is similar to the physiologic 20-40 mmHg partial oxygen pressure for peripheral tissues.

In a series of experiments it was demonstrated that adhesion formation decreased by 50% when 0.7-1% of oxygen was added to the CO2 pneumoperitoneum. Adding 2-4% of oxygen to the CO2 pneumoperitoneum completely prevented this effect. This observation is consistent with the oxygen tensions known to induce hypoxia inducible factor (HIF) and with the normal physiologic peripheral partial oxygen tension around 20-40 mm Hg. (6) In addition, CO2 resorbtion was profoundly affected by adding 2-4% of oxygen in our rabbit model. (7) From these studies we concluded that during CO2 pneumoperitoneum the progressively increasing resorbtion of CO2 is completely prevented by adding 2-4% of oxygen.
4. Pneumoperitoneum and the mesothelial barrier The effect of pneumoperitoneum upon CO2 resorbtion and adhesion formation are consistent with mesothelial hypoxia. This hypoxia causes the large, flat mesothelial cells to retract and bulge thus exposing increasingly large areas of extra cellular matrix (ECM) in between the cells as demonstrated in mice and rats. (8) This moreover may facilitate malignant tumor implantation. Where it has been suggested to affect adversely intraperitoneal infections. (9-11)
5. Insufflation with oxygen We will use a premixed bottle of CO2 + 4% oxygen to insufflate the abdomen. The mixture is stable.

4 % of oxygen obviously does not cause an electrosurgical risk since air contains 20% of oxygen. Also the eventual accidental intravenous perfusion of 1L min would result in the perfusion of 0.04 L/min of oxygen which is considered harmless.

Hypothesis:

We assume that decreasing the hypoxic damage to the mesothelium by adding 4% of oxygen to the CO2 pneumoperitoneum will decrease the inflammatory reaction and therefore post-operative pain and faster normalisation of inflammation parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

addition of 4% oxygen to the carbon dioxide pneumoperitoneum

Group Type EXPERIMENTAL

addition of 4% oxygen

Intervention Type PROCEDURE

addition of 4% oxygen to the carbon dioxide pneumoperitoneum

2

pure carbon dioxide pneumoperitoneum

Group Type ACTIVE_COMPARATOR

carbon dioxde

Intervention Type PROCEDURE

classic pneumoperitoneum with 100 % carbon dioxide

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

addition of 4% oxygen

addition of 4% oxygen to the carbon dioxide pneumoperitoneum

Intervention Type PROCEDURE

carbon dioxde

classic pneumoperitoneum with 100 % carbon dioxide

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject has signed a written informed consent to participate in the study and has agreed to follow instructions and complete all required questionnaires
* Females, 18 years of age or older
* She has to undergo a planned laparoscopy for mentioned indications with a duration that exceeds 60 minutes

Exclusion Criteria

* Pregnancy
* Immunodeficiency
* Refuse or unable to sign informed consent
* Chronic diseases (i.e. COPD, Crohn, cardiac…)
* Mental diseases
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Gasthuisberg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jasper Verguts

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Koninckx, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven, campus Gasthuisberg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven, campus gasthuisberg

Leuven, Vlaams Brabant, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PK-001

Identifier Type: -

Identifier Source: org_study_id